Financial Daily from THE HINDU group of publications
Tuesday, Jan 06, 2004
News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

 Corporate - Announcements


Elder board approves GDR/FCCB issue

Our Bureau

Mumbai , Jan. 5

ELDER Pharmaceuticals plans to issue GDRs up to $15 million or foreign currency convertible bonds up to $15 million or a combination of both.

At a board meeting held here on Monday, the company board has decided to issue the GDR subject to shareholders' approval, informed a company notification to the exchange.

More Stories on : Announcements | Overseas Borrowings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Sun Pharma to set up two new R&D units

Suven Life Sciences EGM clears sub-division of shares
Wockhardt files new drug application
Elder board approves GDR/FCCB issue
L&T bags $30-m order in UAE
Post-demerger cement biz — L&T's paid-up capital to go down to Rs 25 cr
IHCL to seek shareholders' nod to raise funds
IVRCL shareholders okay preferential offer
NCCL to issue preferential shares
Rallis to raise Rs 90 cr through pref shares
Amway comes under scanner of Drug Control authorities
TVS Motor seeks to patent new engine technology
Haldia Petro's debt recast exercise in final lap
NCL Seccolor merged with Alltek Coating
Aurobindo Pharma promoter sells 1.4 pc stake
ONGC board okays Rs 900-cr investment in extraction plant
TVS Motor plans 2 units in Asean region
BIFR gives Vadilal time to reach agreement with secured creditors
Delay in debt revamp plan holds up Duncans' recovery
Tata Group to focus on global biz this year
Strike not to impact Kennametal profit for now, says MD
Valji eyeing TN, Kerala markets
Eicher posts 52% increase in December sales
Tata Motors sales up 67 pc in Dec

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line